14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $227.75 $262.51 Friday, 3rd May 2024 UTHR stock ended at $262.40. This is 1.65% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.57% from a day low at $255.93 to a day high of $262.51.
90 days $208.62 $262.51
52 weeks $204.44 $262.51

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Nov 02, 2023 $225.37 $228.95 $222.45 $228.18 301 439
Nov 01, 2023 $211.70 $227.23 $210.00 $224.08 1 037 441
Oct 31, 2023 $221.32 $222.88 $217.99 $222.86 388 381
Oct 30, 2023 $221.97 $222.72 $219.07 $220.63 227 403
Oct 27, 2023 $224.65 $224.65 $218.50 $219.23 267 859
Oct 26, 2023 $223.64 $225.92 $221.89 $224.40 257 836
Oct 25, 2023 $226.47 $229.35 $222.78 $224.50 196 424
Oct 24, 2023 $224.82 $227.24 $223.40 $227.23 169 956
Oct 23, 2023 $223.94 $225.82 $223.04 $224.15 231 276
Oct 20, 2023 $226.72 $227.53 $224.89 $225.43 183 665
Oct 19, 2023 $230.52 $230.52 $223.50 $225.82 220 729
Oct 18, 2023 $236.31 $236.31 $230.00 $230.31 215 321
Oct 17, 2023 $232.67 $239.24 $232.52 $236.77 309 953
Oct 16, 2023 $233.48 $233.82 $231.49 $232.90 128 203
Oct 13, 2023 $232.99 $234.04 $229.97 $233.16 167 069
Oct 12, 2023 $234.63 $234.63 $230.00 $232.20 218 261
Oct 11, 2023 $230.07 $235.32 $230.07 $234.58 261 608
Oct 10, 2023 $230.82 $232.28 $228.68 $230.33 249 415
Oct 09, 2023 $231.81 $232.61 $228.79 $231.11 182 985
Oct 06, 2023 $228.04 $235.48 $227.95 $234.34 368 859
Oct 05, 2023 $221.41 $228.63 $221.41 $228.29 273 839
Oct 04, 2023 $221.54 $222.54 $220.11 $221.93 141 665
Oct 03, 2023 $220.00 $221.84 $217.62 $221.49 207 860
Oct 02, 2023 $224.33 $226.47 $220.79 $222.14 263 313
Sep 29, 2023 $227.13 $227.76 $224.78 $225.87 297 080
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT